Israel Englander’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Israel Englander’s Portfolio TBIO Stock Details TBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-30,096	Closed	-$829K	–	7571
2021 Q2	$829K	Sell	30,096 -242,412	-89%	-$4.76M	﹤0.01%	4843
2021 Q1	$4.49M	Sell	272,508 -63,613	-19%	-$1.45M	﹤0.01%	2695
2020 Q4	$6.2M	Sell	336,121 -441,450	-57%	-$7.9M	﹤0.01%	2238
2020 Q3	$10.6K	Sell	777,571 -392,207	-34%	-$6.05M	0.01%	1199
2020 Q2	$21M	Buy	+1,169,778	New	+$17.6M	0.03%	703
2018 Q4	–	Sell	-81,863	Closed	-$819K	–	4366
2018 Q3	$819K	Sell	81,863 -27,788	-25%	-$324K	﹤0.01%	2981
2018 Q2	$1.39M	Buy	+109,651	New	+$1.33M	﹤0.01%	2649

Israel Englander's TBIO Position: Q3 2021 in Review

Israel Englander sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 30,096 shares — an estimated $829K sold.

Israel Englander first reported a position in TBIO in Q2 2018 and held it in 7 quarters. The position peaked at $21M in Q2 2020. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.

Israel Englander reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Israel Englander sold 30,096 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $829K.
Israel Englander first reported a position in Translate Bio, Inc. Common Stock in Q2 2018 and held it in 7 quarters.
Israel Englander's Translate Bio, Inc. Common Stock position peaked at $21M in Q2 2020.
0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.

Based on Millennium Management's 13F filing for Q3 2021, filed 15 Nov 2021.